| Overview |
| bs-9674R-APC-Cy5.5 |
| MYLIP Polyclonal Antibody, APC-Cy5.5 Conjugated |
| WB, IF(IHC-P) |
| Human, Mouse, Rat |
| Specifications |
| APC-Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human MYLIP |
| 51-150/445 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 29116 |
| Q8WY64 |
| Cell membrane |
| MIR; IDOL; E3 ubiquitin-protein ligase MYLIP; Inducible degrader of the LDL-receptor; Myosin regulatory light chain interacting protein; MYLIP; BZF1; BM-023; PP5242 |
| E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of myosin regulatory light chain (MRLC), LDLR, VLDLR and LRP8. Activity depends on E2 enzymes of the UBE2D family. Proteasomal degradation of MRLC leads to inhibit neurite outgrowth in presence of NGF by counteracting the stabilization of MRLC by saposin-like protein (CNPY2/MSAP) and reducing CNPY2-stimulated neurite outgrowth. Acts as a sterol-dependent inhibitor of cellular cholesterol uptake by mediating ubiquitination and subsequent degradation of LDLR. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
Powered by Bioz